Figure 2

Biocompatibility assay and TEM image of the cellular distribution of GGMPN. A: Photographs of RBC suspensions in the presence of various reagents; a) 10 mg/L GGMPN for 1 h, b) 1 mg/L miR-122 (same concentration as loaded on GGMPN) was transfected with Lipofectamine 2000 for 1 h, c) untreated control, d) treated with 10 mg/L GGMPN for 5 h (Scale bar =20 μm). B: Characterization of sub-cellular distribution of gold nanoparticles by TEM and EDS; a, c) TEM image of gold nanoparticles in tumor cells treated with or without 10 mg/L GGMPN, b, d) EDS analysis of gold nanoparticles distributed in tumor cells treated with or without 10 mg/L GGMPN ( Scale bar =50 nm). C: a) SEM image of HepG2 cells after GGMPN treatment (during 1 h); b) SEM image of HepG2 cells transfected with miR-122 (1 mg/L, the same concentration as loaded on GGMNP) (during 1 h); c) Morphology of HepG2 cells after GGMPN treatments by microscope assays.